Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2018.Aug.15

OBI received notice from patent attorney’s office that product patent for OBI-3424 named "DNA alkylating agents" has been approved by IP Australia

2018.Jul.30

Clarification on the news article by Commercial Times

2018.Jul.27

Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial

2018.Jul.08

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

2018.Jun.27

Announcement on the board resolution at Annual General Meeting 2018

2018.May.16

Amendment on the announcement for 2018 Annual General Meeting (discussion notes)

2018.May.11

The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle cash-increase of common shares to issue overseas depository receipts

2018.May.11

The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle private placement of common shares at the Annual General Meeting

2018.May.11

Amendment on the announcement for 2018 Annual General Meeting

2018.May.11

Announcement of change of accountant due to internal adjustment of the accounting firm

News

Latest News

Events

Latest events